NRC Health (NRC) SEC Filings & Earnings Calls
EquiReason read 19 NRC Health SEC filings in the last 12 months. Latest: 8-K on 2026-10-19 — CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 485.1M
- P/E TTM
- 88.9
- Dividend yield
- 2.7%
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
19 Oct 20268-K · 5.02CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed.open
Risks flagged
CEO dual role may indicate temporary leadership gap in finance function.
“CEO appointed as interim principal financial officer; no permanent CFO named.”
11 Aug 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
CFO departure may disrupt financial operations and investor confidence
“CFO resignation effective Aug 28, 2026; search for replacement initiated.”
4 Aug 202610-QNRC Health reported Q2 2026 results with 4% revenue growth and 11% TRCV growth, but operating income swung to a loss due to $7.1M in stock-based compensation related to executive leadership. Adjusted net income grew 7% YoY.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $35M | +4% y/y |
| Net income (loss) · Q2-2026 | $-3M | |
| Adjusted EBITDA · Q2-2026 | $9M | -8% y/y |
| Total Recurring Contract Value (TRCV) · 2026-06-30 | $152M | +11% y/y |
| Operating cash flow · 6M-2026 | $9M | +56% y/y |
| Free cash flow · 6M-2026 | $5M | |
| Capital expenditures · 6M-2026 | $3M | -47% y/y |
Risks flagged
Executive compensation overhang
“Selling, general, and administrative expenses increased to $22.9 million for the 2026 period, from $17.7 million for the same period in 2025. The increase was primarily driven by $7.1 million of higher stock-based compensation expense related to executive leadership.” · word for word
Operating loss
“Operating income (loss) $(3,238) in Q2 2026 vs $1,588 in Q2 2025.”
28 Jul 20268-K · 2.02Total Recurring Contract Value (TRCV) $152M (+11% y/y); Revenue $35M (+4% y/y); GAAP Net Loss $-3Mearningsopen
Figures in the filing · each found in the filing text
| Total Recurring Contract Value (TRCV) · Q2-2026 | $152M | +11% y/y |
| Revenue · Q2-2026 | $35M | +4% y/y |
| GAAP Net Loss · Q2-2026 | $-3M | |
| Adjusted Net Income · Q2-2026 | $7M | |
| Adjusted EBITDA · Q2-2026 | $9M | |
| Free Cash Flow · Q2-2026 | $100000.00 | |
| Operating Cash Flow · Q2-2026 | $1M | |
| GAAP Net Loss Per Diluted Share · Q2-2026 | $-0.15 | |
| Adjusted Net Income Per Diluted Share · Q2-2026 | $0.31 |
Risks flagged
GAAP net loss and low free cash flow due to one-time adjustment items
“GAAP net loss ($3.3M); free cash flow $0.1M reflecting $2.9M cash payment for Adjustment Items”
8 May 2026DEF 14ANRC Health filed its 2026 proxy statement (DEF 14A) with proposals to declassify the board, remove supermajority voting requirements, and approve executive compensation.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $137M | |
| Net Income · FY2025 | $12M |
Risks flagged
Insider ownership concentration risk
“As of March 31, 2026, approximately 38.2% of our outstanding common stock was held by the Common Property Trust (the “Trust”), the principal holder of shares previously owned by Mr. Hays, and approximately 47.6% of our outstanding common stock was held by the Trust and other entities controlled by trustees or special power holders for the benefit of members ” · word for word
6 May 202610-QRevenue $35M (+4% y/y); Net income $3M (-44% y/y); Total Recurring Contract Value $152M (+13% y/y)open
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $35M | +4% y/y |
| Net income · Q1-2026 | $3M | -44% y/y |
| Total Recurring Contract Value · 2026-03-31 | $152M | +13% y/y |
| Operating margin · Q1-2026 | 16.0% | |
| Adjusted EBITDA · Q1-2026 | $9M | -9% y/y |
| Free cash flow · Q1-2026 | $5M | +46% y/y |
| Operating cash flow · Q1-2026 | $7M | +8% y/y |
Risks flagged
Executive transition costs
“The increase was primarily driven by $1.4 million of higher stock‑based compensation related to executive leadership and approximately $0.5 million of executive salary expense that was not present in the prior‑year period.” · word for word
One-time compensation charges
“The amendments and related bonuses are expected to result in approximately $9.4 million of expense during the second quarter of 2026.” · word for word
28 Apr 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
One-time expense may impact earnings, but non-cash portion accelerates future expense.
“consisting of (i) approximately $6.5 million of non-cash accelerated equity compensation expense... and (ii) approximately $2.9 million of cash bonus expense.”
28 Apr 202610-K/ARevenue $137M; Net Income $12Mopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $137M | |
| Net Income · FY2025 | $12M |
28 Apr 20268-K · 2.02NRC Health Q1 2026: Revenue $34.8M (+4% YoY); TRCV $152.1M (+13%); Adj EBITDA $9.4M (27% margin); first YoY revenue growth since 2023; largest deal in history.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $35M | +4% y/y |
| Total Recurring Contract Value (TRCV) · Q1-2026 | $152M | +13% y/y |
| Adjusted EBITDA · Q1-2026 | $9M | |
| GAAP Diluted EPS · Q1-2026 | $0.14 | -44% y/y |
| Adjusted Diluted EPS · Q1-2026 | $0.21 | |
| Operating Cash Flow · Q1-2026 | $7M | +8% y/y |
| Free Cash Flow · Q1-2026 | $5M | |
| Operating Income · Q1-2026 | $6M | -35% y/y |
Risks flagged
GAAP net income declined 44% YoY due to higher SG&A and interest expense
“Net income $3.2M vs $5.8M YoY; SG&A $13.4M vs $10.4M; interest expense $1.3M vs $0.9M”
27 Mar 2026SC 13D/AFounder/Chairman Michael D. Hays's beneficial ownership dropped below 5% due to relinquishment of reacquisition rights over 582,688 shares held by irrevocable trusts.open
Figures in the filing · each found in the filing text
| Total Recurring Contract Value · FY2026 | $170M |
5 Mar 20268-K · 7.01Total Recurring Contract Value (TRCV) $152M (+13% y/y)open
Figures in the filing · each found in the filing text
| Total Recurring Contract Value (TRCV) · Q1-2026 | $152M | +13% y/y |
3 Feb 20268-K · 2.02Total Recurring Contract Value (TRCV) $144M (+8% y/y); Revenue $35M; GAAP Net Income $2Mearningsopen
Figures in the filing · each found in the filing text
| Total Recurring Contract Value (TRCV) · Q4-2025 | $144M | +8% y/y |
| Revenue · Q4-2025 | $35M | |
| GAAP Net Income · Q4-2025 | $2M | |
| Adjusted Net Income · Q4-2025 | $3M | |
| Adjusted EBITDA · Q4-2025 | $9M | |
| Operating Cash Flow · Q4-2025 | $7M | +13% y/y |
| GAAP Net Income Per Diluted Share · Q4-2025 | $0.08 | |
| Adjusted Net Income Per Diluted Share · Q4-2025 | $0.16 | |
| Full Year Revenue · FY2025 | $137M | |
| Full Year GAAP Net Income · FY2025 | $12M |
7 Nov 202510-QNRC Health reported Q3 2025 revenue of $34.6M (-3% YoY) and YTD revenue of $102.2M (-4% YoY), with operating margin stable at 22% in Q3 but down 600bps YTD to 18%. TRCV grew 8% YoY to $141.7M.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $35M | -3% y/y |
| Revenue · 9M-2025 | $102M | -4% y/y |
| Net Income · FY2025 | $12M | |
| Total Recurring Contract Value · Q3-2025 | $142M | +8% y/y |
| Operating Income · Q3-2025 | $8M | -3% y/y |
| Operating Income · 9M-2025 | $18M | -30% y/y |
| Cash provided by operating activities · 9M-2025 | $19M | -32% y/y |
| Capital Expenditures · 9M-2025 | $10M |
Risks flagged
Revenue decline from existing clients
“Revenue in the 2025 period decreased compared to the 2024 period by $1.2 million. This was mainly from decreased recurring revenue of $1.6 million in our existing client base” · word for word
High leverage and interest expense
“Total other expense increased in the 2025 period compared to the 2024 period primarily due to higher interest expense of $0.8 million mainly from higher borrowings outstanding on our Delayed Draw Term Loan” · word for word
Working capital deficit
“We had a working capital deficit of $18.2 million and $16.3 million on September 30, 2025 and December 31, 2024, respectively.” · word for word
27 Oct 20258-K · 2.02Total Recurring Contract Value (TRCV) $142M (+8% y/y); Revenue $35M; GAAP Net Income $4Mearningsopen
Figures in the filing · each found in the filing text
| Total Recurring Contract Value (TRCV) · Q3-2025 | $142M | +8% y/y |
| Revenue · Q3-2025 | $35M | |
| GAAP Net Income · Q3-2025 | $4M | |
| Adjusted Net Income · Q3-2025 | $5M | |
| Adjusted EBITDA · Q3-2025 | $11M | +11% y/y |
| Operating Cash Flow · Q3-2025 | $14M | +46% y/y |
| GAAP Net Income Per Diluted Share · Q3-2025 | $0.18 | |
| Adjusted Net Income Per Diluted Share · Q3-2025 | $0.23 |
NRC Health — questions
- What did NRC Health file recently?
- 19 SEC filings in the last 12 months. Latest: 8-K on 2026-10-19 — CEO Trent Green appointed as interim principal financial officer; no compensation changes; no arrangements or understandings disclosed.
Every figure on this page comes from NRC Health's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.